Kornitzer Capital Management Inc. KS increased its stake in shares of Progyny, Inc. (NASDAQ:PGNY – Free Report) by 15.7% in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 976,501 shares of the company’s stock after purchasing an additional 132,672 shares during the quarter. Kornitzer Capital Management Inc. KS’s holdings in Progyny were worth $16,366,000 as of its most recent filing with the SEC.
Other institutional investors have also made changes to their positions in the company. Quarry LP raised its stake in shares of Progyny by 1,900.0% during the 2nd quarter. Quarry LP now owns 880 shares of the company’s stock worth $25,000 after purchasing an additional 836 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of Progyny in the 2nd quarter valued at $44,000. Mendota Financial Group LLC bought a new position in Progyny during the third quarter valued at about $56,000. Cambridge Trust Co. acquired a new stake in shares of Progyny in the first quarter worth about $95,000. Finally, 1620 Investment Advisors Inc. bought a new stake in shares of Progyny during the 2nd quarter worth about $97,000. 94.93% of the stock is currently owned by institutional investors and hedge funds.
Progyny Trading Down 0.1 %
NASDAQ PGNY traded down $0.02 on Thursday, reaching $16.36. The company’s stock had a trading volume of 105,520 shares, compared to its average volume of 1,365,205. Progyny, Inc. has a 52 week low of $13.93 and a 52 week high of $42.08. The firm has a market cap of $1.48 billion, a PE ratio of 26.00, a price-to-earnings-growth ratio of 1.43 and a beta of 1.44. The business has a 50-day moving average price of $18.39 and a 200 day moving average price of $24.13.
Wall Street Analyst Weigh In
PGNY has been the topic of a number of recent analyst reports. JPMorgan Chase & Co. reduced their target price on Progyny from $31.00 to $22.00 and set an “overweight” rating for the company in a report on Thursday, September 19th. Leerink Partners lowered their target price on shares of Progyny from $25.00 to $21.00 and set a “market perform” rating on the stock in a research note on Thursday, September 19th. BTIG Research lowered shares of Progyny from a “buy” rating to a “neutral” rating in a research report on Wednesday, August 7th. Leerink Partnrs downgraded Progyny from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, August 7th. Finally, Canaccord Genuity Group cut Progyny from a “buy” rating to a “hold” rating and cut their price objective for the stock from $37.00 to $24.00 in a research report on Wednesday, August 7th. Seven research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $27.73.
Read Our Latest Report on Progyny
About Progyny
Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.
Read More
- Five stocks we like better than Progyny
- Investing in the High PE Growth Stocks
- Breakout Alert: Qualcomm Just Hit The Rally Button
- Stock Average Calculator
- Mercado Libre Shares Go on Sale: Is Now the Time to Buy?
- Which Wall Street Analysts are the Most Accurate?
- Atlassian Is Up +60% in Three Months—What’s Causing the Rally?
Want to see what other hedge funds are holding PGNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Progyny, Inc. (NASDAQ:PGNY – Free Report).
Receive News & Ratings for Progyny Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Progyny and related companies with MarketBeat.com's FREE daily email newsletter.